Bessemer Group Inc. Increases Stake in Pacira Pharmaceuticals Inc (PCRX)

Bessemer Group Inc. lifted its position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 9,056.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,265 shares of the company’s stock after acquiring an additional 24,000 shares during the period. Bessemer Group Inc. owned 0.06% of Pacira Pharmaceuticals worth $1,043,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Rehmann Capital Advisory Group grew its stake in shares of Pacira Pharmaceuticals by 28.5% in the 4th quarter. Rehmann Capital Advisory Group now owns 2,217 shares of the company’s stock worth $95,000 after buying an additional 492 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Pacira Pharmaceuticals by 22.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,950 shares of the company’s stock worth $127,000 after buying an additional 538 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of Pacira Pharmaceuticals by 3,735.8% in the 4th quarter. Meeder Asset Management Inc. now owns 4,603 shares of the company’s stock worth $198,000 after buying an additional 4,483 shares during the last quarter. Great West Life Assurance Co. Can grew its stake in shares of Pacira Pharmaceuticals by 39.9% in the 4th quarter. Great West Life Assurance Co. Can now owns 5,364 shares of the company’s stock worth $222,000 after buying an additional 1,529 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of Pacira Pharmaceuticals by 12.2% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 5,602 shares of the company’s stock worth $241,000 after buying an additional 610 shares during the last quarter.

PCRX has been the topic of several recent research reports. Wedbush set a $91.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, January 29th. ValuEngine upgraded Pacira Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 2nd. Zacks Investment Research downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Mizuho downgraded Pacira Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Friday, February 1st. Finally, National Securities assumed coverage on Pacira Pharmaceuticals in a research note on Tuesday, February 12th. They set a “sell” rating on the stock. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus target price of $53.25.



Shares of PCRX opened at $39.29 on Friday. The company has a current ratio of 7.88, a quick ratio of 7.08 and a debt-to-equity ratio of 0.90. Pacira Pharmaceuticals Inc has a 12 month low of $26.95 and a 12 month high of $55.00. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of 135.48, a price-to-earnings-growth ratio of 2.37 and a beta of 1.49.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, February 28th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.07 by $0.40. Pacira Pharmaceuticals had a positive return on equity of 3.94% and a negative net margin of 0.14%. The business had revenue of $95.12 million for the quarter, compared to the consensus estimate of $93.69 million. During the same period last year, the business posted $0.38 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. On average, equities research analysts expect that Pacira Pharmaceuticals Inc will post 0.66 earnings per share for the current year.

In other news, Director Mark A. Kronenfeld purchased 1,700 shares of the stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of $38.97 per share, with a total value of $66,249.00. Following the acquisition, the director now directly owns 9,277 shares of the company’s stock, valued at $361,524.69. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.90% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://dakotafinancialnews.com/2019/03/15/bessemer-group-inc-increases-stake-in-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Story: Benefits of owning preferred stock

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.